vs
Essex Property Trust（ESS）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
Essex Property Trust的季度营收约是Prestige Consumer Healthcare Inc.的1.7倍（$479.6M vs $283.4M），Essex Property Trust净利率更高（17.9% vs 16.5%，领先1.4%），Essex Property Trust同比增速更快（5.5% vs -2.4%），过去两年Essex Property Trust的营收复合增速更高（6.0% vs 1.2%）
Essex Property Trust是一家公开上市的房地产投资信托企业，重点布局美国西海岸优质不动产市场，核心投资标的为加利福尼亚州及西雅图大都会区的公寓类物业，在长租公寓的投资、运营及管理领域拥有深厚的行业积累与资源优势。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
ESS vs PBH — 直观对比
营收规模更大
ESS
是对方的1.7倍
$283.4M
营收增速更快
ESS
高出7.9%
-2.4%
净利率更高
ESS
高出1.4%
16.5%
两年增速更快
ESS
近两年复合增速
1.2%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $479.6M | $283.4M |
| 净利润 | $85.7M | $46.7M |
| 毛利率 | 70.0% | 55.5% |
| 营业利润率 | 31.7% | 29.1% |
| 净利率 | 17.9% | 16.5% |
| 营收同比 | 5.5% | -2.4% |
| 净利润同比 | -71.6% | -23.5% |
| 每股收益（稀释后） | $1.24 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESSPBH
| Q4 25 | $479.6M | $283.4M | ||
| Q3 25 | $473.3M | $274.1M | ||
| Q2 25 | $469.8M | $249.5M | ||
| Q1 25 | $464.6M | $296.5M | ||
| Q4 24 | $454.5M | $290.3M | ||
| Q3 24 | $450.7M | $283.8M | ||
| Q2 24 | $442.4M | $267.1M | ||
| Q1 24 | $426.9M | $277.0M |
净利润ESSPBH
| Q4 25 | $85.7M | $46.7M | ||
| Q3 25 | $172.7M | $42.2M | ||
| Q2 25 | $231.5M | $47.5M | ||
| Q1 25 | $212.8M | $50.1M | ||
| Q4 24 | $301.7M | $61.0M | ||
| Q3 24 | $125.5M | $54.4M | ||
| Q2 24 | $99.0M | $49.1M | ||
| Q1 24 | $285.1M | $49.5M |
毛利率ESSPBH
| Q4 25 | 70.0% | 55.5% | ||
| Q3 25 | 69.2% | 55.3% | ||
| Q2 25 | 70.7% | 56.2% | ||
| Q1 25 | 69.6% | 57.3% | ||
| Q4 24 | 70.0% | 55.5% | ||
| Q3 24 | 69.5% | 55.5% | ||
| Q2 24 | 70.8% | 54.7% | ||
| Q1 24 | 69.7% | 54.8% |
营业利润率ESSPBH
| Q4 25 | 31.7% | 29.1% | ||
| Q3 25 | 44.5% | 29.1% | ||
| Q2 25 | 59.5% | 28.8% | ||
| Q1 25 | 55.3% | 29.8% | ||
| Q4 24 | 67.0% | 31.7% | ||
| Q3 24 | 28.6% | 29.7% | ||
| Q2 24 | 31.1% | 27.0% | ||
| Q1 24 | 31.0% | 29.7% |
净利率ESSPBH
| Q4 25 | 17.9% | 16.5% | ||
| Q3 25 | 36.5% | 15.4% | ||
| Q2 25 | 49.3% | 19.0% | ||
| Q1 25 | 45.8% | 16.9% | ||
| Q4 24 | 66.4% | 21.0% | ||
| Q3 24 | 27.8% | 19.2% | ||
| Q2 24 | 22.4% | 18.4% | ||
| Q1 24 | 66.8% | 17.9% |
每股收益（稀释后）ESSPBH
| Q4 25 | $1.24 | $0.97 | ||
| Q3 25 | $2.56 | $0.86 | ||
| Q2 25 | $3.44 | $0.95 | ||
| Q1 25 | $3.16 | $1.00 | ||
| Q4 24 | $4.00 | $1.22 | ||
| Q3 24 | $1.84 | $1.09 | ||
| Q2 24 | $1.45 | $0.98 | ||
| Q1 24 | $4.25 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $76.2M | $62.4M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $5.5B | $1.8B |
| 总资产 | $13.2B | $3.5B |
| 负债/权益比越低杠杆越低 | — | 0.56× |
8季度趋势，按日历期对齐
现金及短期投资ESSPBH
| Q4 25 | $76.2M | $62.4M | ||
| Q3 25 | $66.0M | $119.1M | ||
| Q2 25 | $58.7M | $139.5M | ||
| Q1 25 | $98.7M | $97.9M | ||
| Q4 24 | $66.8M | $50.9M | ||
| Q3 24 | $71.3M | $51.5M | ||
| Q2 24 | $55.2M | $34.3M | ||
| Q1 24 | $499.0M | $46.5M |
总债务ESSPBH
| Q4 25 | — | $1.0B | ||
| Q3 25 | $6.4B | $993.1M | ||
| Q2 25 | $6.4B | $992.7M | ||
| Q1 25 | $6.8B | $992.4M | ||
| Q4 24 | — | $992.0M | ||
| Q3 24 | $6.4B | $1.1B | ||
| Q2 24 | $6.2B | $1.1B | ||
| Q1 24 | $6.6B | $1.1B |
股东权益ESSPBH
| Q4 25 | $5.5B | $1.8B | ||
| Q3 25 | $5.6B | $1.8B | ||
| Q2 25 | $5.6B | $1.9B | ||
| Q1 25 | $5.6B | $1.8B | ||
| Q4 24 | $5.5B | $1.8B | ||
| Q3 24 | $5.4B | $1.7B | ||
| Q2 24 | $5.5B | $1.7B | ||
| Q1 24 | $5.5B | $1.7B |
总资产ESSPBH
| Q4 25 | $13.2B | $3.5B | ||
| Q3 25 | $13.2B | $3.4B | ||
| Q2 25 | $13.2B | $3.4B | ||
| Q1 25 | $13.2B | $3.4B | ||
| Q4 24 | $12.9B | $3.3B | ||
| Q3 24 | $12.6B | $3.3B | ||
| Q2 24 | $12.5B | $3.3B | ||
| Q1 24 | $12.9B | $3.3B |
负债/权益比ESSPBH
| Q4 25 | — | 0.56× | ||
| Q3 25 | 1.15× | 0.54× | ||
| Q2 25 | 1.14× | 0.54× | ||
| Q1 25 | 1.22× | 0.54× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | 1.18× | 0.61× | ||
| Q2 24 | 1.13× | 0.65× | ||
| Q1 24 | 1.19× | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.1B | $78.3M |
| 自由现金流经营现金流 - 资本支出 | — | $75.3M |
| 自由现金流率自由现金流/营收 | — | 26.6% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | 12.53× | 1.68× |
| 过去12个月自由现金流最近4个季度 | — | $267.2M |
8季度趋势，按日历期对齐
经营现金流ESSPBH
| Q4 25 | $1.1B | $78.3M | ||
| Q3 25 | $342.6M | $57.5M | ||
| Q2 25 | $216.1M | $79.0M | ||
| Q1 25 | $281.5M | $61.8M | ||
| Q4 24 | $1.1B | $65.1M | ||
| Q3 24 | $316.2M | $69.8M | ||
| Q2 24 | $218.9M | $54.8M | ||
| Q1 24 | $314.9M | $66.9M |
自由现金流ESSPBH
| Q4 25 | — | $75.3M | ||
| Q3 25 | — | $55.4M | ||
| Q2 25 | — | $78.2M | ||
| Q1 25 | — | $58.4M | ||
| Q4 24 | — | $63.5M | ||
| Q3 24 | — | $67.8M | ||
| Q2 24 | — | $53.6M | ||
| Q1 24 | — | $63.8M |
自由现金流率ESSPBH
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 31.3% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 21.9% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 20.1% | ||
| Q1 24 | — | 23.0% |
资本支出强度ESSPBH
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 1.1% |
现金转化率ESSPBH
| Q4 25 | 12.53× | 1.68× | ||
| Q3 25 | 1.98× | 1.36× | ||
| Q2 25 | 0.93× | 1.66× | ||
| Q1 25 | 1.32× | 1.23× | ||
| Q4 24 | 3.54× | 1.07× | ||
| Q3 24 | 2.52× | 1.28× | ||
| Q2 24 | 2.21× | 1.12× | ||
| Q1 24 | 1.10× | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESS
暂无分部数据
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
